Secondary Hormone Therapy For Castration Resistant Prostate Cancer

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

For patients with metastatic hormone-sensitive prostate cancer, physicians are combining docetaxel-based therapies or secondary hormonal therapies, says George. Moving forward, there may be an opportunity to combine both of those agents together, especially in patients with high-volume, extensive-stage disease.

For patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on agents such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi), physicians are faced with selecting the optimal second-line therapy. Prognostic factors and tumor burden are 2 big components that must be considered, says George. Within this population, there are patients with a high tumor burden who are going undetected, and, as a result, are not receiving therapy that is aggressive enough. Mild progression of symptoms is still progression, he adds. Following progression on frontline therapy, the median survival of a patient with mCRPC is 18 months. By being cognizant of these changes, physicians can take a more proactive approach and try to maintain a patient’s performance status at 0 or 1 for as long as possible.

Source :

Dr. George on Sequential Therapy in Metastatic Prostate Cancer
Growing Industry of Castration Resistant Prostate Cancer Treatment Market 2019 - 2025 Expected to Reach Remarkable CAGR
Enzalutamide, ADT combination improves radiographic PFS in metastatic prostate cancer
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU
Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial
Pfizer, Astellas Pharma announce positive results from phase 3 ARCHES trial of Xtandi in men with metastatic hormone-sensitive prostate cancer
Enzalutamide Leads to Extended Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Targeted radiation therapy yields high response rates in metastatic prostate cancer